Oncology Times Broadcast News
Aromatase Inhibitor Better Than Tamoxifen For Initial Adjuvant Therapy For Hormone Receptor Positive Breast Cancer, But Compliance An Issue!
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:06:57
- Mais informações
Informações:
Sinopse
Oncology Times Broadcast News Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue! Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer–analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.
